HomeMission | Investigators | Transgenic Mouse Facility | PCR Core Facility | Human Tumor BankCareer Opps
Funding Opportunities | Cancer Cell Biology Track | SCCCB Pre-doctoral Fellowship | Seminars | News | Related Links | Site Index



 


 

Mark R. Emmett, Ph.D.
Professor
Biochemistry & Molecular Biology
email: 
mremmett@utmb.edu


Dr. Emmett's current research specializes in identification of novel therapeutic targets and biomarkers in oncology (esp. neuro-oncology). He has established a multi-disciplinary research group enabling a systems biological approach integrating geneomics, transcriptomics, proteomics, glycomics, lipidomics, metabolomics and phenotypic responses to the study of cancer focusing on the identification of novel biomarkers and therapeutic targets.


  1. Proteomic Investigation of Glioblastoma Cell Lines Treated with Wild-Type p53 and Cytotoxic Chemotherapy Demonstrates an Association between Galectin-1 and p53 Expression, Maja Puchades, Carol L. Nilsson, Mark R. Emmett, Kenneth D. Aldape, Yongjie Ji, Frederick F. Land, Ta-Jen Liu, and Charles A. Conrad, Journal of Proteome Research, 2007, 6: 869-875.
  2. Method for Lipidomic Analysis: p53 Expression Modulation of Sulfatide, Ganglioside and Phospholipid Composition of U87 MG Glioblastoma Cells, Huan He, Charles A. Conrad, Carol L. Nilsson, Yongjie Ji, Tanner M. Schaub, Alan G. Marshall and Mark R. Emmett, Analytical Chemistry, 2007, 79: 8423-8430.
  3. KIT Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients, Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M.; He, Y.-A.; Jacques, S. L.; Lunney, E. A.; McTigue, M; Molina, D.; Quenzer, T. A.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H.-M.; Demetri, G. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1542-1547.
  4. Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, Irinotecan, Huan He, Carol L. Nilsson, Mark R. Emmett, Yongjie Ji, Alan G. Marshall, Roger A. Kroes, Joseph R. Moskal, Howard Colman, Frederick F. Lang, and Charles A. Conrad, Glycoconjugates. 2010, 27(1): 27-38.
  5. Glycomic and transcriptomic response of GSC-11 glioblastoma stem cells to STAT-3 phosphorylation inhibition and serum-induced differentiation, Huan He, Carol L. Nilsson, Mark R. Emmett, Alan G. Marshall, Roger A. Kroes, Joseph R. Moskal, Yongjie Ji, Howard Colman, Waldemar Priebe, Frederick F. Lang, and Charles A. Conrad, J. Proteomics Research, 2010, 9: 2098-2108.
  6. Overexpression of ST6GalNAcV, a ganglioside-specific a2,6 sialyltransferase, inhibits glioma invasivity. Roger A. Kroes, Huan He, Mark R. Emmett, Carol L. Nilsson, Alan G. Marshall, and Joseph R. Moskal, Proceedings of the National Academy of Sciences, 2010, 107 (28): 12646-12651.

 
HomeMission | Investigators | Transgenic Mouse Facility | PCR Core Facility | Human Tumor BankCareer Opps
Funding Opportunities | Cancer Cell Biology Track | SCCCB Pre-doctoral Fellowship | Seminars | News | Related Links | Site Index

This site published by Donna Davis for the Sealy Center for Cancer Cell Biology.
Copyright   2002  The University of Texas Medical Branch. Please review our privacy policy and Internet guidelines.

  Last Revised:  January 18, 2008